IL-12 gene-modified bone marrow cell therapy suppresses the development of experimental metastatic prostate cancer. | Cancer Gene Ther;14(10): 819-27, 2007 Oct. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

IL-12 gene-modified bone marrow cell therapy suppresses the development of experimental metastatic prostate cancer.

Wang, H; Yang, G; Timme, T L; Fujita, T; Naruishi, K; Frolov, A; Brenner, M K; Kadmon, D; Thompson, T C.

Affiliation

Wang H; Scott Department of Urology, Baylor College of Medicine, Houston, TX 77030, USA.

Cancer Gene Ther ; 14(10): 819-27, 2007 Oct.

Article in En | MEDLINE | ID: mdl-17627292

Subject(s)

Search on Google

Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Bone Neoplasms / Bone Marrow Cells / Interleukin-12 / Disease Models, Animal / Lung Neoplasms Type of study: Prognostic_studies Limits: Animals Language: En Journal: Cancer Gene Ther Journal subject: GENETICA MEDICA / NEOPLASIAS / TERAPEUTICA Year: 2007 Document type: Article Affiliation country:

Search on Google

Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Bone Neoplasms / Bone Marrow Cells / Interleukin-12 / Disease Models, Animal / Lung Neoplasms Type of study: Prognostic_studies Limits: Animals Language: En Journal: Cancer Gene Ther Journal subject: GENETICA MEDICA / NEOPLASIAS / TERAPEUTICA Year: 2007 Document type: Article Affiliation country: